Summary Background Alzheimer’s disease and related dementias (ADRD) affect nearly 6.9 million Americans, with the number expected to triple by 2050, while disease-modifying therapies remain unavailable. Drug repurposing, which identifies new indications for already approved medications, offers a more efficient and cost...
Qiong Wu, Lu Li, Yu-Qing Lei et al.· EBioMedicine· 0 citations
An international workshop was convened in London, Canada in 2025 to review the evidence for existing or evolving biomarkers suitable for the detection of either ALS or FTD pathobiology prior to phenoconversion and/or predict phenoconversion in at risk individuals.
Michael J. Strong, Neil S. Donison, A. Al-Chalabi et al.· Brain : a journal of neurolo...· 0 citations
Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.
T. Paranhos, Yuta Katsumi, M. Brickhouse et al.· Neurology· 0 citations
In this case report, areas of extensive amyloid clearance following amyloid targeting therapy were associated with less downstream neuropathological change and appear to preferentially occur in gyral crests.
Christopher A. Brown, John L. Robinson, Sandhitsu R. Das et al.· Journal of the American Medi...· 0 citations
Greater TDP-43 burden was most closely associated with antemortem clinical decline rather than cumulative aggregation through the disease course, suggesting that the temporal dynamics of protein aggregation may differ among FTLD proteinopathies, with implications for the interpretation of FTLD-Tau and FTLD-TDP‑specific...
R. Magee, Sharon X. Xie, DT Ohm et al.· Neurology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
